ATR inhibition sensitizes HPV− and HPV+ head and neck squamous cell carcinoma to Cisplatin (cas 15603-27-1)

Add time:09/04/2019    Source:sciencedirect.com

ObjectivesCisplatin is commonly used in the treatment of head and neck squamous cell carcinoma (HNSCC), and the repair of cisplatin-induced DNA damage involves activation of the DNA damage response protein ataxia telangiectasia and Rad3-related (ATR). Resistance to cisplatin therapy exacerbates adverse toxicities and is associated with poor outcomes. Since repair of cisplatin-induced DNA damage contributes to resistance, we hypothesized that inhibition of ATR using AZD6738, a well-tolerated and orally-bioavailable inhibitor, would enhance the sensitivity of HNSCC cells and tumors to cisplatin.

We also recommend Trading Suppliers and Manufacturers of Cisplatin (cas 15603-27-1). Pls Click Website Link as below: cas 15603-27-1 suppliers

Prev:Effect of Cisplatin (cas 15603-27-1) on pancreas and testies in Wistar rats: biochemical parameters and histology
Next:Review articleBeyond Cisplatin (cas 15603-27-1): Combination therapy with arsenic trioxide)